TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SKAN Group AG ( (CH:SKAN) ) has issued an update.
SKAN Group AG announced that it will not meet its revenue and profit expectations for 2025 due to project delays, resulting in a decline in net revenue and a lower EBITDA margin for the year. Despite these setbacks, the company reports a positive order intake, particularly in oncology and biotechnology sectors, laying a strong foundation for a successful fiscal year 2026. The company’s medium- and long-term growth prospects remain positive, supported by structural market growth and a robust project pipeline.
The most recent analyst rating on (CH:SKAN) stock is a Hold with a CHF57.00 price target. To see the full list of analyst forecasts on SKAN Group AG stock, see the CH:SKAN Stock Forecast page.
More about SKAN Group AG
SKAN is a pioneer in aseptic and aseptic-toxic manufacturing processes for the (bio-)pharmaceutical industry, specializing in high-quality isolator systems for drug filling under strict sterility standards. The company also provides process support, services, and consumables, serving pharmaceutical and biotech industries, CMOs, and research laboratories worldwide. Founded in 1968, SKAN employs around 1700 people, with a significant presence in the Life Sciences Hub of the Basel region and subsidiaries in several countries.
Average Trading Volume: 29,572
Technical Sentiment Signal: Hold
Current Market Cap: CHF1.12B
For an in-depth examination of SKAN stock, go to TipRanks’ Overview page.